NEO6860: A Phase I, Double-Blind, Placebo-Controlled, Single and Multiple Oral Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Healthy Male and Female Subjects

Trial Profile

NEO6860: A Phase I, Double-Blind, Placebo-Controlled, Single and Multiple Oral Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Healthy Male and Female Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Sep 2017

At a glance

  • Drugs NEO 6860 (Primary)
  • Indications Musculoskeletal pain; Neuropathic pain; Osteoarthritis; Visceral pain
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 20 Sep 2017 According to a NEOMED Institute media release, results from this trial will be presented at the Pain & Migraine Therapeutic Summit.
    • 07 Feb 2017 Results published in the Journal of Pain : official journal of the American Pain Society.
    • 14 May 2016 Results presented at the 35th Annual Scientific Meeting of the American Pain Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top